Efficacy of HP-3070, A Once-Daily Asenapine Transdermal System, in the Treatment of Adults with Schizophrenia: A PANSS Five-Factor Analysis

References

• GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet Psychiatry. 2022;9(2):137–150. doi:10.1016/S2215-0366(21)00395-3
   PubMed Web of Science ®Google Scholar
• Citrome L. A review of the pharmacology, efficacy and tolerability of recently approved and upcoming oral antipsychotics: an evidence-based medicine approach. CNS Drugs. 2013;27(11):879–911. doi:10.1007/s40263-013-0105-7
   PubMed Web of Science ®Google Scholar
• Faden J, Citrome L. Schizophrenia: one name, many different manifestations. Med Clin North Am. 2023;107(1):61–72. doi:10.1016/j.mcna.2022.05.005
   PubMed Web of Science ®Google Scholar
• Allergan USA, Inc. SAPHRIS® (asenapine) sublingual tablets [prescribing information]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/022117s020s021lbl.pdf. Accessed January 26, 2023.
   Google Scholar
• Musselman M, Faden J, Citrome L. Asenapine: an atypical antipsychotic with atypical formulations. Ther Adv Psychopharmacol. 2021;11:20451253211035269. doi:10.1177/20451253211035269
   Web of Science ®Google Scholar
• Citrome L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int J Clin Pract. 2009;63(12):1762–1784. doi:10.1111/j.1742-1241.2009.02228.x
   PubMed Web of Science ®Google Scholar
• Citrome L, Zeni CM, Correll CU. Patches: established and emerging transdermal treatments in psychiatry. J Clin Psychiatry. 2019;80(4):18. doi:10.4088/JCP.18nr12554
   Web of Science ®Google Scholar
• Hisamitsu Pharmaceutical Co., Inc. SECUADO® (asenapine) transdermal system [prescribing information]. Available from: https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=685eaf44-5944-4f38-afba-0a4fc0b3462b&type=pdf. Accessed January 26, 2023.
   Google Scholar
• Noven Pharmaceuticals, Inc. SECUADO® (asenapine) transdermal system, the first-and-only transdermal patch for the treatment of adults with schizophrenia, is now available in the U.S. Available from: https://www.noven.com/wp-content/uploads/2020/04/PR041320.pdf. Accessed August 4, 2022.
   Google Scholar
• Stevens JR, Justin Coffey M, Fojtik M, Kurtz K, Stern TA. The use of transdermal therapeutic systems in psychiatric care: a primer on patches. Psychosomatics. 2015;56(5):423–444. doi:10.1016/j.psym.2015.03.007
   PubMed Web of Science ®Google Scholar
• Citrome L, Walling DP, Zeni CM, et al. Efficacy and safety of HP-3070, an asenapine transdermal system, in patients with schizophrenia: a phase 3, randomized, placebo-controlled study. J Clin Psychiatry. 2021;82(1):20m13602 doi:10.4088/JCP.20m13602.
   Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi:10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Lehoux C, Gobeil MH, Lefèbvre AA, Maziade M, Roy MA. The five-factor structure of the PANSS: a critical review of its consistency across studies. Clin Schizophr Relat Psychoses. 2009;3(3):103–110. https://www.clinicalschizophrenia.net/articles/the-fivefactor-structure-of-the-panss-a-critical-review-of-its-consistency-across-studies.pdf.
   Google Scholar
• Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry. 1997;58(12):538–546. doi:10.4088/JCP.v58n1205
   PubMed Web of Science ®Google Scholar
• Citrome L, Komaroff M, Starling B, Byreddy S, Terahara T, Hasebe M. Efficacy of HP-3070, an asenapine transdermal system, on symptoms of hostility in adults with schizophrenia: a post hoc analysis of a 6-week phase 3 study. J Clin Psychiatry. 2022;83(4):21m14355. doi:10.4088/JCP.21m14355
   PubMed Web of Science ®Google Scholar
• Kane JM, Cohen M, Zhao J, Alphs L, Panagides J. Efficacy and safety of asenapine in a placebo- and haloperidol-controlled trial in patients with acute exacerbation of schizophrenia. J Clin Psychopharmacol. 2010;30(2):106–115. doi:10.1097/JCP.0b013e3181d35d6b
   PubMed Web of Science ®Google Scholar
• Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry. 2007;68(10):1492–1500. doi:10.4088/JCP.v68n1004
   PubMed Web of Science ®Google Scholar
• Takekita Y, Hiraoka S, Iwama Y, et al. Divergence of dose-response with asenapine: a cluster analysis of randomized, double-blind, and placebo control study. CNS Spectr. 2022;27(3):369–377. doi:10.1017/S1092852921000043
   PubMed Web of Science ®Google Scholar
• Suzuki K, Castelli M, Komaroff M, Starling B, Terahara T, Citrome L. Pharmacokinetic profile of the asenapine transdermal system (HP-3070). J Clin Psychopharmacol. 2021;41(3):286–294. doi:10.1097/JCP.0000000000001383
   PubMed Web of Science ®Google Scholar
• Citrome L. Asenapine review, part II: clinical efficacy, safety and tolerability. Expert Opin Drug Saf. 2014;13(6):803–830. doi:10.1517/14740338.2014.908183
   PubMed Web of Science ®Google Scholar
• Szegedi A, Verweij P, van Duijnhoven W, Mackle M, Cazorla P, Fennema H. Meta-analyses of the efficacy of asenapine for acute schizophrenia: comparisons with placebo and other antipsychotics. J Clin Psychiatry. 2012;73(12):1533–1540. doi:10.4088/JCP.11r07596
   PubMed Web of Science ®Google Scholar
• Kinoshita T, Bai YM, Kim JH, Miyake M, Oshima N. Efficacy and safety of asenapine in Asian patients with an acute exacerbation of schizophrenia: a multicentre, randomized, double-blind, 6-week, placebo-controlled study. Psychopharmacology. 2016;233(14):2663–2674. doi:10.1007/s00213-016-4295-9
   PubMed Web of Science ®Google Scholar
• Buchanan RW, Panagides J, Zhao J, et al. Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol. 2012;32(1):36–45. doi:10.1097/JCP.0b013e31823f880a
   PubMed Web of Science ®Google Scholar
• Potkin SG, Phiri P, Szegedi A, Zhao J, Alphs L, Cazorla P. Long-term effects of asenapine or olanzapine in patients with persistent negative symptoms of schizophrenia: a pooled analysis. Schizophr Res. 2013;150(2–3):442–449. doi:10.1016/j.schres.2013.08.024
   PubMed Web of Science ®Google Scholar
• Citrome L, Meng X, Hochfeld M. Efficacy of iloperidone in schizophrenia: a PANSS five-factor analysis. Schizophr Res. 2011;131(1–3):75–81. doi:10.1016/j.schres.2011.05.018
   PubMed Web of Science ®Google Scholar